On August 13, Changchun hi tech (000661. SZ), a domestic growth hormone leader, disclosed the semi annual report of 2021. The company realized an operating revenue of 4.963 billion yuan, a year-on-year increase of 26.71%; The net profit attributable to the parent company was 1.923 billion yuan, a year-on-year increase of 46.85%.
However, the Red Star capital Bureau found that after the share price of Changchun high tech reached a high of 522.17 yuan / share on May 17 this year, its share price continued to decline due to rumors such as the purchase of growth hormone in the market, reaching a minimum of 264 yuan / share on August 6, down more than 43%.
As of today’s noon closing, Changchun high tech news was 312.60 yuan / share, and the market value of the company was 126.5 billion yuan.
Net profit increased by nearly 50% in the first half of the year
Growth hormone contributes more than 95%
Public information shows that the main business of Changchun high tech is the R & D, production and sales of biopharmaceuticals and Chinese patent medicines, supplemented by real estate development, property management and services. Pharmaceutical products cover multiple pharmaceutical segments such as innovative genetic engineering pharmaceuticals, new vaccines and modern traditional Chinese medicine, and are the main source of the company’s performance.
According to the semi annual report, Changchun hi tech realized an operating revenue of 4.963 billion yuan in the first half of 2021, a year-on-year increase of 26.71%; The net profit attributable to the parent company was 1.923 billion yuan, a year-on-year increase of 46.85%; The operating cash flow was 1.305 billion yuan, a year-on-year increase of 60.48%.
The performance of Changchun hi tech in the first half of the year mainly came from the contributions of two subsidiaries, among which Kinsey pharmaceutical, a subsidiary mainly engaged in growth hormone, contributed most of the profits. According to the data, Kinsey pharmaceutical achieved an operating revenue of 3.788 billion yuan and a net profit of 1.859 billion yuan; In addition, the subsidiary Baike biology realized an operating revenue of 582 million yuan and a net profit of 138 million yuan.
Kinsay pharmaceutical is the first recombinant human growth hormone production enterprise in China. Changchun hi tech holds 99.5% of the shares and has long been committed to the R & D and production of recombinant human growth hormone, a therapeutic drug for children’s dwarfism. Up to now, Kinsey pharmaceutical is the only growth hormone manufacturer in China with a complete product line of powder injection, water injection and long-term water injection. Its long-acting water injection is the only long-acting growth hormone variety in China. The dosage forms and specifications of the products approved in the domestic market are the most complete.
Changchun hi tech said that during the reporting period, Kinsey pharmaceutical reasonably formulated, timely optimized and adjusted sales policies, improved patient satisfaction, strengthened patient management through continuous service and whole process management, and continued to do a good job in the development of new patients, which effectively improved the company’s business performance.
At the same time, in the second quarter, a large-scale centralized vaccination of Xinguan vaccine was gradually implemented nationwide. The warehouses and vaccination personnel resources of local CDCs were relatively tight. The subsidiary Baike biology made efforts to overcome the above adverse factors, actively promoted the sales of varicella vaccine products, and made efforts to ensure the stability of production and operation.